Further examination of the correlations among IL‐6, D‐dimer, and PD‐1 efficacy in lung cancer patients stratified by gender revealed a significant association of IL‐6 levels with risk of PFS in male but not female patients. This evidence concerns the gene IL6 and lung cancer.